1. Market Research
  2. > Pharmaceutical Market Trends
  3. > South Africa Pharmaceuticals and Healthcare Report Q4 2015

South Africa Pharmaceuticals and Healthcare Report Q4 2015

  • October 2015
  • -
  • Business Monitor International
  • -
  • 128 pages

Includes 3 FREE quarterly updates

BMI View: Delays in implementing South Africa's national health insurance scheme and intellectualproperty reform will negatively impact patients' access to medical treatments in the short term. Despitethese impediments, innovative drugmakers and private healthcare providers will continue to seekopportunities in the interim, given the relatively high proportion of spending on patented drugs and privatehealthcare services.Headline Expenditure Projections-Pharmaceuticals: ZAR39.79bn (USD3.67bn) in 2014 to ZAR43.84bn (USD3.47bn) in 2015; +10.2% inlocal currency terms and -5.3% in US dollar terms. Forecast in US dollar terms revised downwards fromlast quarter.

Table Of Contents

South Africa Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (South Africa 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (South Africa 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (South Africa 2011-2019) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (South Africa 2011-2019) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (South Africa 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (South Africa 2011-2019) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (South Africa 2011-2019) 26
OTC Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (South Africa 2011-2019) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (South Africa 2013-2019) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (South Africa 2013-2019) 31
Key Risks To BMI's Forecast Scenario 32
Macroeconomic Forecasts 33
Economic Analysis 33
Table: Economic Activity (South Africa 2010-2019) 37
Industry Risk Reward Indices 38
Middle East and Africa Risk/Reward Index 38
South Africa Risk/Reward Index 45
Rewards 45
Risks 45
Market Overview 47
Industry Trends And Developments 50
Epidemiology 50
Healthcare Sector 53
Public Healthcare Sector 54
Private Healthcare Sector 55
Healthcare Infrastructure 59
Table: Healthcare Resources (South Africa 2009-2014) 60
Table: Healthcare Personnel (South Africa 2009-2014) 60
Table: Healthcare Activity (South Africa 2009-2014) 61
Research and Development Sector 61
Clinical Trials 62
Vaccines 63
Traditional African Medicine 64
Telemedicine 65
Regulatory Development 66
Table: Drug Classification System 66
Regulatory Developments 69
Intellectual Property Environment 71
Pricing Regime 74
Table: Tiered Pharmaceutical Pricing System Is Better Than A Flat Fixed Mark-Up 74
Reimbursement Regime 76
Competitive Landscape 77
Research-Based Pharmaceutical Industry 77
Pharmaceutical Retail Sector 80
Private Healthcare Market 82
Company Profile 84
Aspen Pharmacare 84
Adcock Ingram 88
Cipla Medpro 93
GlaxoSmithKline 96
Merck and Co 101
Novartis 104
Pfizer 106
Ranbaxy 109
Roche 112
Sanofi 114
Demographic Forecast 117
Demographic Outlook 117
Table: Population Headline Indicators (South Africa 1990-2025) 118
Table: Key Population Ratios (South Africa 1990-2025) 118
Table: Urban/Rural Population and Life Expectancy (South Africa 1990-2025) 119
Table: Population By Age Group (South Africa 1990-2025) 119
Table: Population By Age Group % (South Africa 1990-2025) 120
Glossary 122
Methodology 124
Pharmaceutical Expenditure Forecast Model 124
Healthcare Expenditure Forecast Model 124
Notes On Methodology 125
Risk/Reward Index Methodology 126
Index Overview 127
Table: Pharmaceutical Risk/Reward Index Indicators 127
Indicator Weightings 128

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.